Sangamo BioSciences | SGMO - Current Liabilities


Sangamo BioSciences reported $47.66M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 595K 218K Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Amgen USD 24.96B 534M Mar/2026
Bayer EUR 33.46B 875M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cipla INR 70.14B 7.16B Mar/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.04M 533K Mar/2026
CSL USD 4.61B 207M Dec/2025
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Grifols EUR 2.37B 156.97M Dec/2025
Ionis Pharmaceuticals USD 717M 66M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Pfizer USD 34.35B 2.64B Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026